US Primary Hyperoxaluria (PH) Drugs Market Report 2023 to 2030

US Primary Hyperoxaluria (PH) Drugs Market Analysis

$ 3999

US Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

ID: IN10USRD107 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Nipun Arora

Buy Now

US Primary Hyperoxaluria (PH) Drugs Market Analysis Summary

US Primary Hyperoxaluria (PH) Drugs Market is valued at around $7.4 Mn in 2022 and is projected to reach $12.44 Mn by 2030, exhibiting a CAGR of 6.7% during the forecast period 2023-2030.

Primary Hyperoxaluria (PH), a rare hereditary condition, is brought on by errors in the metabolism of glyoxylates, which build up oxalate mostly in the kidneys and result in end-stage renal failure. It can be divided into three categories based on the several genes involved: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Hematuria, urinary tract infections, and recurring kidney stones are possible symptoms (UTIs). In contrast to children, kidney stones are frequently the initial symptom of primary hyperoxaluria in adults. Other signs and symptoms include renal failure, chronic kidney disease, recurrent urinary tract infections, severe side discomfort, abdominal pain, and blood in the urine.

The treatment approach for Primary Hyperoxaluria involves various strategies, including dietary modifications, supportive care, and pharmacological interventions. The current treatment options include Lumasiran (Oxlumo) developed by alnylam Pharmaceuticals, which is a subcutaneously administered it is RNA interference (RNAi) medication for PH1 that has received FDA approval. It functions by concentrating on and preventing the synthesis of the oxalate-producing enzyme glycolate oxidase.

Dicerna's RNAi Therapeutic: Dicerna Pharmaceuticals is developing an investigational RNAi therapeutic, DCR-PHXC, for the treatment of PH1, PH2, and PH3. This therapy aims to reduce the production of glycolate oxidase or lactate dehydrogenase, enzymes involved in oxalate production, depending on the specific type of PH.

(ALLN-177) Reloxaliase developed by Allena Pharmaceuticals in this drug Oxalate is specifically broken down in the GI tract by the enzyme oxalate decarboxylase in ALLN-177, enabling the body to expel it through the stool. By preventing oxalate from building up in the body, this mechanism lessens the burden on the kidneys to filter and remove oxalate in the urine.

One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

Market Dynamics

Market Drivers

The increase in people suffering from the disease globally is one of the major drivers of the primary hyperoxaluria medication market's growth. The growth in special designations from the regulatory body and growing demand for drugs such as calcium oxalate urinary inhibitors, thiazide diuretics, and others, for treating various illness problems, both contribute to the market's rapid expansion.

The development of technology that offers medicines for the particular treatment of the disease, the rise of acquisition strategies and corporate alliances for research efforts, and all of these have an effect on the market. The hyperoxaluria drug industry also benefits from growing public and private sector support, expanding disease-specific new therapeutic demand, and growing public awareness. The creation of novel treatment options also increases the market participants' possibilities of making money.

Market Restraints

On the other hand, market growth is likely to be constrained by the high cost of diagnosing and treating primary hyperoxaluria. Complex Disease Management, Reimbursement and Market Access issues. Due to the restricted operational revenue potential for targeted therapeutic research and development by many pharmaceutical companies, the primary hyperoxaluria medication business is predicted to experience difficulties.

Key players

Alnylam Pharmaceuticals, Inc. OxThera AB Dicerna Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc. Epygenix Therapeutics, Inc. Translate Bio, Inc. Omeros Corporation Prothena Biosciences Inc. Retrophin, Inc. Chiesi Farmaceutici S.p.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Primary Hyperoxaluria (PH) Drugs Market

By Treatment Type

Reloxaliase
Thiazide Diuretics
Supplements

By Drug Type:

Prescriptions
Over-the-counter drugs

By Population Type:

Children
Adults

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.